|
1
|
World Health Organization (WHO), .
Classification of Tumours of the Digestive System. 3. 4th edition.
WHO; Geneva: 2010
|
|
2
|
Chen J, Zhou L, Gao J, Lu T, Wang J, Wu H
and Liang Z: Clinicopathological characteristics and mutation
spectrum of colorectal adenocarcinoma with mucinous component in a
chinese cohort: Comparison with classical adenocarcinoma. Front
Oncol. 10:9172020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li ZP, Liu XY, Kao XM, Chen YT, Han SQ,
Huang MX, Liu C, Tang XY, Chen YY, Xiang D, et al:
Clinicopathological characteristics and prognosis of colorectal
mucinous adenocarcinoma and nonmucinous adenocarcinoma: A
surveillance, epidemiology, and end results (SEER) population-based
study. Ann Transl Med. 8:2052020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Park JS, Huh JW, Park YA, Cho YB, Yun SH,
Kim HC, Lee WY and Chun HK: Prognostic comparison between mucinous
and nonmucinous adenocarcinoma in colorectal cancer. Medicine
(Baltimore). 94:e6582015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reynolds IS, Furney SJ, Kay EW, McNamara
DA, Prehn JHM and Burke JP: Meta-analysis of the molecular
associations of mucinous colorectal cancer. Br J Surg. 106:682–691.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hugen N, Simons M, Halilović A, van der
Post RS, Bogers AJ, Marijnissen-van Zanten MA, de Wilt JH and
Nagtegaal ID: The molecular background of mucinous carcinoma beyond
MUC2. J Pathol Clin Res. 1:3–17. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li X, Sun K, Liao X, Gao H, Zhu H and Xu
R: Colorectal carcinomas with mucinous differentiation are
associated with high frequent mutation of KRAS or BRAF mutations,
irrespective of quantity of mucinous component. BMC Cancer.
20:4002020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ott C, Gerken M, Hirsch D, Fest P,
Fichtner-Feigl S, Munker S, Schnoy E, Stroszczynski C, Vogelhuber
M, Herr W, et al: Advanced mucinous colorectal cancer:
Epidemiology, prognosis and efficacy of chemotherapeutic treatment.
Digestion. 98:143–152. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Verhulst J, Ferdinande L, Demetter P and
Ceelen W: Mucinous subtype as prognostic factor in colorectal
cancer: A systematic review and meta-analysis. J Clin Pathol.
65:381–388. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Catalano V, Bergamo F, Cremolini C,
Vincenzi B, Negri F, Giordani P, Alessandroni P, Intini R,
Stragliotto S, Rossini D, et al: Clinical impact of first-line
bevacizumab plus chemotherapy in metastatic colorectal cancer of
mucinous histology: A multicenter, retrospective analysis on 685
patients. J Cancer Res Clin Oncol. 146:493–501. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang A, Yang Y, Shi JY, Li YK, Xu JX,
Cheng Y and Gu J: Mucinous adenocarcinoma: A unique
clinicopathological subtype in colorectal cancer. World J
Gastrointest Surg. 13:1567–1583. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miyakawa T, Kawamura H, Honda M, Takano Y,
Kinuta S, Kamiga T, Yamazaki S, Muto A, Shiraso S, Yamashita N, et
al: Impact of histological subtype on prognosis in stage IV
colorectal cancer: A population-based cohort study. PLoS One.
17:e02646522022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Meguid RA, Slidell MB, Wolfgang CL, Chang
DC and Ahuja N: Is there a difference in survival between right-
versus left-sided colon cancers? Ann Surg Oncol. 15:2388–2394.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Saravani K, Salarzaei M and Parooie F:
Effect of KRAS and BRAF mutations in metastatic colorectal cancer
patients: A systematic review and meta-analysis based on tumor
sidedness and KRAS subtypes. Hum Antibodies. 29:275–284. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Catalano V, Loupakis F, Graziano F,
Torresi U, Bisonni R, Mari D, Fornaro L, Baldelli AM, Giordani P,
Rossi D, et al: Mucinous histology predicts for poor response rate
and overall survival of patients with colorectal cancer and treated
with first-line oxaliplatin- and/or irinotecan-based chemotherapy.
Br J Cancer. 100:881–887. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Maisano R, Azzarello D, Maisano M, Mafodda
A, Bottari M, Egitto G and Nardi M: Mucinous histology of colon
cancer predicts poor outcomes with FOLFOX regimen in metastatic
colon cancer. J Chemother. 24:212–216. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Moretto R, Morano F, Ongaro E, Rossini D,
Pietrantonio F, Casagrande M, Antoniotti C, Corallo S, Marmorino F,
Cortiula F, et al: Lack of benefit from Anti-EGFR treatment in RAS
and BRAF wild-type metastatic colorectal cancer with mucinous
histology or mucinous component. Clin Colorectal Cancer.
18:116–124. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou YW, Long YX, Chen Y, Liu JY, Pu D,
Huang JY, Bi F, Li Q, Gou HF and Qiu M: First-line therapy of
bevacizumab plus chemotherapy versus cetuximab plus chemotherapy
for metastatic colorectal cancer patients with mucinous
adenocarcinoma or mucinous component. Cancer Med. 10:3388–3402.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang C, Sandhu J and Fakih M: Mucinous
histology is associated with resistance to anti-EGFR therapy in
patients with left-sided RAS/BRAF wild-type metastatic colorectal
cancer. Oncologist. 27:104–109. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Washington K: Excisional biopsy
(polypectomy), local excision (transanal disk excision), colectomy
(total, partial, or segmental resection), rectal resection (low
anterior resection or abdominoperineal resection). College of
American Pathologists; Northfield, IL: 2012
|
|
21
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Negri FV, Wotherspoon A, Cunningham D,
Norman AR, Chong G and Ross PJ: Mucinous histology predicts for
reduced fluorouracil responsiveness and survival in advanced
colorectal cancer. Ann Oncol. 16:1305–1310. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mekenkamp LJ, Heesterbeek KJ, Koopman M,
Tol J, Teerenstra S, Venderbosch S, Punt CJA and Nagtegaal ID:
Mucinous adenocarcinomas: Poor prognosis in metastatic colorectal
cancer. Eur J Cancer. 48:501–509. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lan YT, Chang SC, Lin PC, Lin CC, Lin HH,
Huang SC, Lin CH, Liang WY, Chen WS, Jiang JK, et al:
Clinicopathological and molecular features of colorectal cancer
patients with mucinous and non-mucinous adenocarcinoma. Front
Oncol. 11:6201462021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
O'Connell E, Reynolds IS, Salvucci M,
McNamara DA, Burke JP and Prehn JHM: Mucinous and non-mucinous
colorectal cancers show differential expression of chemotherapy
metabolism and resistance genes. Pharmacogenomics J. 21:510–519.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Reynolds IS, O'Connell E, Fichtner M,
McNamara DA, Kay EW, Prehn JHM, Furney SJ and Burke JP: Mucinous
adenocarcinoma is a pharmacogenomically distinct subtype of
colorectal cancer. Pharmacogenomics J. 20:524–532. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cantero-Recasens G, Alonso-Marañón J,
Lobo-Jarne T, Garrido M, Iglesias M, Espinosa L and Malhotra V:
Reversing chemorefraction in colorectal cancer cells by controlling
mucin secretion. Elife. 11:e739262022. View Article : Google Scholar : PubMed/NCBI
|
